entertainment -WSS

entertainment

author：leisure time 2025-09-06 04:15:24 - browse：211

Treeline Northwest — AP Photo/Ted S. Warren

Josh Bilenker’s last company, Loxo Oncology, was purchased by Eli Lilly for $8 billion. No surprise, then, that his next effort has already raised at least $473 million in funding from private investors even before telling the public what, exactly, it is working on.

Treeline Biosciences, the new venture by Bilenker and Jeffrey Engelman, formerly Novartis’s top cancer researcher, has hired more than 130 people across three research sites in little more than a year, according to a company blog post, regulatory filings, and STAT reporting.

Treeline’s website doesn’t mention a single drug target or disease. In a paper published last year in Nature Cancer, Engelman and several colleagues reviewed the history of a class of cancer drugs called PI3 kinase inhibitors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Ukrainian soldiers say they owe lives to US

WSS

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

ADA: All diabetes patients should be screened for liver condition

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

Bernie brings in new pharma CEOs to talk drug prices

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Texas Medical Board asked to define abortion emergency exception

Wikipedia

entertainment

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Drug repurposing or repositioning? The language matters

Wildfire smoke map: Which US cities are forecast to be impacted by fires burning in Canada

Malaria cases in Florida and Texas: Here’s what you need to know

Federal board approves $12.7 billion budget for Puerto Rico as island shakes off bankruptcy

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Johnson & Johnson sued for allegedly overpaying for workers' drugs

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The simple reason for the increase in autism diagnosis

hotspot

Top private equity targets in 2023: cardiology, clinical trials, lasers

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

Problems with a popular proposal to regulate AI in health care

Why Novartis is going to walk from its acquisition of MorphoSys

Why Novartis is going to walk from its acquisition of MorphoSys

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

entertainment

knowledge

leisure time

hotspot